COVID-19 Omicron variant-inhibitory in silico evidence for phytocompounds of an ancient Ayurvedic formulation

23 February 2022, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

The emerging SARS-COV-2 variants and the global COVID-19 outbreak underscore the urgent need for prophylactics and improved antivirals. Scientists are racing to develop vaccines and antiviral drugs. While vaccinations will be the primary pandemic prophylactic and, appropriate antiviral medications will be needed as a treatment strategy. The variant strains of the virus spawned the second and third waves in several countries, and it affected universally. Antiviral drugs with novel mechanisms of action are still needed to combat emerging SARS-CoV-2 mutations. The present research confirmed in silico the prospective efficacy of an ancient Ayurvedic formulation made for prophylactic and treatment material against symptoms similar to the COVID-19 Wuhan_Hu_1st strain, which had been provided with similar in silico evidence in our earlier report. Clinical studies with safe chemical cocktails may have prospects for countries where the practice of Ayurveda is not legal.

Keywords

SARS CoV-2
Omicron
Spike glycoprotein
Angiotensin-converting enzyme 2
Ayurvedic formulation
Molecular docking

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.